These results confirm that p53 null status seems to be necessary for doxorubicin to activate NF-κB -dependent transcription in breast cancer cells both in vitro and ex vivo, although other factors might be limiting NF-κB response to DNA damage. The gene discussed is TP53; the disease is breast cancer.